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Eosinophil-derived neurotoxin and clinical outcomes with 
mepolizumab in severe eosinophilic asthma
To the Editor,
Severe eosinophilic asthma is characterized by increased blood 
eosinophil levels and recurrent exacerbations, and often associated 
with nasal polyposis.1 Eosinophil cationic protein (ECP) and eosino-
phil-derived neurotoxin (EDN), granule proteins released by eosino-
phils, are markers of eosinophil activation and have been identified 
as potential biomarkers of type 2 eosinophilic disease in patients 
with asthma.2-4
The anti-interleukin (IL)-5 monoclonal antibody mepolizumab has 
been shown to reduce peripheral blood eosinophil counts (PBEC) and 
asthma exacerbations versus placebo in clinical studies.5-7 Elevated 
PBEC and frequent exacerbations are key determinants for predict-
ing patients with severe asthma who are most likely to respond to 
mepolizumab;6,8 however, identifying additional biomarkers may 
enhance patient selection. This post hoc analysis of data from the 
Phase III MENSA study (GSK ID: 115588; NCT01691521)7 investi-
gated the relationship between baseline type 2 biomarkers and clini-
cal outcomes in patients with severe asthma receiving mepolizumab.
MENSA was a randomized, double-blind trial in patients 
aged ≥12 years with severe eosinophilic asthma.7 Patients were ran-
domized (1:1:1) to receive mepolizumab 75mg intravenously (IV) or 
100 mg subcutaneously (SC), or placebo every 4 weeks for 32 weeks 
plus standard of care (see Appendix S1 for further details). Levels of 
the biomarkers EDN, ECP, chemokines (CCL-13, CCL-17, CCL-22 and 
eotaxin-1), periostin and IL-13 were determined using serum samples 
taken at Weeks 0 (randomization) and 32 (exit).
Endpoints included the following: annualized rate of clinically 
significant exacerbations (defined as worsening of asthma requiring 
systemic corticosteroids for ≥3 days and/or hospitalization/emer-
gency department visit); ratio to baseline of PBEC; change from 
baseline in prebronchodilator forced expiratory volume in 1 second 
(FEV1), asthma control questionnaire (ACQ)-5 score, St George's 
Respiratory Questionnaire (SGRQ) total score (all at Week 32). Post 
hoc analysis assessments included baseline biomarker levels by PBEC 
subgroups (<150, 150-<300, 300-<500, ≥500 cells/μL) and presence 
of nasal polyposis at screening, correlation between biomarker lev-
els and PBEC at baseline, and change from baseline in biomarker lev-
els at Week 32. Additionally, the ratio of PBEC to baseline, changes 
from baseline in FEV1, ACQ-5 and SGRQ scores, and annualized ex-
acerbations (all at Week 32) were assessed in high (>median) and low 
(≤median) EDN (median = 57.6 μg/L) or ECP (median = 21.06 μg/L) 
subgroups at baseline (initial results determined which biomarkers 
were analysed further [EDN and ECP]). The annualized exacerbation 
rate was also assessed in high/low EDN and ECP subgroups further 
stratified by PBEC; baseline EDN level and baseline PBEC as pre-
dictors of response to mepolizumab treatment were also evaluated. 
Statistical analyses are described in Appendix S1. The MENSA trial 
was conducted in accordance with all applicable country-specific 
regulatory requirements, and all patients provided written informed 
consent. Ethical approval was not required for this post hoc analysis.
In MENSA, 194 patients received mepolizumab 100 mg SC, 191 
received mepolizumab 75 mg IV and 191 received placebo. At base-
line, levels of most biomarkers increased with increasing PBEC, and 
the biomarkers EDN, ECP and IL-13 showed a moderately positive 
correlation with PBEC (Table S1). Patients with nasal polyposis also 
had numerically higher baseline PBEC, EDN, ECP, CCL-13, CCL-17 
and IL-13 levels than those without nasal polyposis (data not shown). 
EDN was reduced by 70% from baseline to Week 32 with mepoli-
zumab versus placebo, with a similar trend noted for ECP (58% re-
duction) (Figure S1A). In contrast, there was a trend for an increase 
in the levels of CCL-13, CCL-17, CCL-22 and eotaxin-1 between base-
line and Week 32 with mepolizumab versus placebo (Figure S1B).
Owing to the positive correlation of EDN and ECP with PBEC, 
and their use as markers of eosinophil activation, we investigated 
clinical outcomes following mepolizumab treatment in patients with 
differing baseline EDN and ECP levels. Baseline PBEC was higher in 
patients with high versus low EDN or ECP levels at baseline and me-
polizumab significantly reduced PBEC between baseline and Week 
32 to a similar extent in both high and low EDN and ECP subgroups 
versus placebo. Mepolizumab-induced improvements in other clini-
cal outcomes were also numerically greater in high versus low base-
line EDN or ECP subgroups (Table S2); as such, EDN and ECP may 
predict improvements in FEV1.
We also found mepolizumab reduced the exacerbation rate versus 
placebo in both baseline EDN subgroups, with a greater reduction in 
patients with high versus low EDN (Figure 1). To further investigate 
whether this effect could be explained in terms of confounding by 
baseline PBEC, subgroups were stratified by baseline PBEC. In pa-
tients with baseline PBEC ≥ 300 cells/µL, there was a larger reduc-
tion in exacerbations with mepolizumab in the high (75%) versus low 
(28%) baseline EDN subgroups. A similar trend was noted between the 
two < 300 cells/µL EDN subgroups. However, no difference was ob-
served in the ECP subgroups. Furthermore, predicted rate ratio mod-
elling of exacerbations demonstrated that a predictive model based on 
baseline PBEC was marginally better than that based on baseline EDN 
in terms of precision and model fit (Figure 2).
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Overall, we found baseline PBEC correlated with baseline EDN 
levels, as reported elsewhere,9 with a more pronounced reduction 
in the placebo-adjusted annualized exacerbation rate with mepoli-
zumab in patients with high versus low baseline EDN levels (trend 
not seen with ECP). Modelling analysis results demonstrated EDN 
levels and the combination of EDN levels, PBEC and treatment in-
teraction did not show improved predictive power versus that of 
PBEC alone for treatment response to mepolizumab regarding ex-
acerbation reduction. This result indicates that the predictive power 
of EDN is largely due to its correlation with baseline PBEC and 
highlights that PBEC remains an important and clinically relevant 
biomarker for identifying patients with severe asthma who are likely 
to respond to mepolizumab treatment.
In conclusion, our results demonstrate that in general, patients 
with higher versus lower EDN levels are likely to have improved re-
sponses to mepolizumab, although further research is needed on the 
role of EDN as a potential biomarker for treatment response to me-
polizumab. However, baseline PBEC has greater precision as a pre-
dictive biomarker of treatment response to mepolizumab than EDN 
and is more widely assessed in clinical practice. Our data provide 
further evidence that PBEC is the most suitable biomarker identified 
to date for identifying patients likely to respond to mepolizumab, 
F I G U R E  1   Ratio of the annual rate of clinically significant exacerbations with mepolizumab 100 mg SC versus placebo by baseline 
biomarker and PBEC subgroup. CI, confidence interval; ECP, eosinophil cationic protein; EDN, eosinophil-derived neurotoxin; PBEC, 
peripheral blood eosinophil count; SC, subcutaneous
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although the identification of additional biomarkers may further aid 
patient selection in the future.
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F I G U R E  2   Predicted rate ratio 
(95% CI) of mepolizumab 100 mg SC 
versus placebo for clinically significant 
exacerbations per year versus (A) baseline 
PBEC, (B) baseline EDN concentration 
and (C) baseline EDN concentration 
adjusted for baseline PBEC and treatment 
interaction. †Akaike information 
criterion; lower values indicate a better 
model fit. Shading indicates 95% CI; 
wider bands indicate lower precision in 
predicting exacerbation rate. All analyses 
performed using a negative binomial 
regression model with covariates: 
treatment, maintenance corticosteroid 
use, exacerbation number in previous 
year. Additional covariates: (A) baseline 
PBEC (square transformation) including 
additional term for treatment interaction; 
(B) baseline EDN concentration 
(square-root transformation) with 
term for treatment interaction; (C) 
baseline EDN concentration (square-
root transformation) with term for 
treatment interaction and baseline PBEC 
(log transformation) with treatment 
interaction. CI, confidence interval; 
EDN, eosinophil-derived neurotoxin; 














PBEC at baseline (cells/µL)
































EDN at baseline (µg/L)





























EDN at baseline (µg/L)

















2088  |     LETTERS TO THE EDITOR
DATA AVAIL ABILIT Y S TATEMENT
Anonymized individual participant data from the study listed within 
this publication and its associated documents can be requested for 










1Global Medical, Global Specialty and Primary Care, GSK House, 
Brentford, Middlesex, UK
2Department of Allergy, Hospital La Paz Institute for Health 
Research (IdiPAZ), Madrid, Spain
3CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain
4Section of Cardiorespiratory and Internal Medicine, 
Department of Medical Sciences, University of Ferrara, Ferrara, 
Italy
5S. Anna University Hospital, Ferrara, Italy
6Harvard Medical School and Asthma Research Center, Brigham 
and Women’s Hospital, Boston, MA, USA
7Biostatistics, GSK, Uxbridge, UK
8Respiratory Discovery Medicine, GSK, Stevenage, UK
9Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, 
USA
10Respiratory Medical Franchise, GSK, Research Triangle Park, 
NC, USA
11Respiratory Medical Franchise, GSK, London, UK
Present address
Frank C. Albers*, * Medical Department, Avillion US Inc., 
Northbrook, IL, USA
Correspondence
Peter Howarth, Global Medical, GSK House, 980 Great West 
Road, Brentford, Middlesex, TW8 9GS, UK.
Email: peter.h.howarth@gsk.com
ORCID
Peter Howarth  https://orcid.org/0000-0003-0619-7927 
Frank C. Albers*  https://orcid.org/0000-0001-7039-4621 
Namhee Kwon  https://orcid.org/0000-0001-5238-0656 
R E FE R E N C E S
 1. Wenzel S. Severe asthma: from characteristics to phenotypes to en-
dotypes. Clin Exp Allergy. 2012;42(5):650-658.
 2. Mogensen I, Alving K, Bjerg A, et al. Simultaneously elevated exhaled 
nitric oxide and serum-eosinophil cationic protein relate to recent 
asthma events in asthmatics in a cross-sectional population-based 
study. Clin Exp Allergy. 2016;46(12):1540-1548.
 3. Gon Y, Ito R, Hattori T, et al. Serum eosinophil-derived neurotoxin: 
correlation with persistent airflow limitation in adults with house-
dust mite allergic asthma. Allergy Asthma Proc. 2015;36(6):e113-120.
 4. Acharya KR, Ackerman SJ. Eosinophil granule proteins: form and 
function. J Biol Chem. 2014;289(25):17406-17415.
 5. GlaxoSmithKline. NUCALA US prescribing information. https://www.
gskso urce.com/pharm a/conte nt/dam/Glaxo Smith Kline /US/en/
Presc ribing_Infor matio n/Nucal a/pdf/NUCAL A-PI-PIL-IFU-COMBI 
NED.PDF. Accessed January 9, 2020.
 6. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab 
add-on therapy on health-related quality of life and markers of asthma 
control in severe eosinophilic asthma (MUSCA): a randomised, dou-
ble-blind, placebo-controlled, parallel-group, multicentre, phase 3b 
trial. Lancet Respir Med. 2017;5(5):390-400.
 7. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients 
with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-1207.
 8. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosin-
ophilic asthma (DREAM): a multicentre, double-blind, placebo-con-
trolled trial. Lancet. 2012;380(9842):651-659.
 9. Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosino-
phil biomarkers by benralizumab in patients with asthma. Respir Med. 
2016;111:21-29.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
DOI: 10.1111/all.14267  
Demonstration of distinct pathways of mast cell-dependent 
inhibition of Treg generation using murine bone marrow-
derived mast cells
To the Editor,
Oral tolerance is the generation of systemic nonresponsiveness 
to an antigen encountered via the gastrointestinal tract. The LEAP 
study demonstrated the effectiveness of this method for prevention 
of peanut allergy in early life.1 Repeated oral food exposure in the 
form of oral immunotherapy (OIT) as a treatment of established 
food allergy is less effective in the induction of true tolerance, 
and protection wanes over time as treatment is stopped.2 Burton 
